ERBB2 and breast cancer: The 70‐gene MammaPrint (MP) test, which has drawn attention among clinicians, is specifically designed to evaluate recurrence risk in early‐stage Hormone Receptor positive (HR+), Human Epidermal Growth Factor Receptor 2 negative (HER2‐) invasive BC patients using formalin‐fixed paraffin‐embedded (FFPE) or fresh frozen tissue.[5, 6, 7] This test estimates the 10‐year risk of distant metastasis and classifies patients into low or high‐risk groups for recurrence.